Paul Delmar
Roche (Switzerland)(CH)
Publications by Year
Research Areas
Alzheimer's disease research and treatments, Dementia and Cognitive Impairment Research, Statistical Methods in Clinical Trials, Health Systems, Economic Evaluations, Quality of Life, Lung Cancer Treatments and Mutations
Most-Cited Works
- → A phase III randomized trial of gantenerumab in prodromal Alzheimer’s disease(2017)561 cited
- → Bevacizumab in Combination With Chemotherapy As First-Line Therapy in Advanced Gastric Cancer: A Biomarker Evaluation From the AVAGAST Randomized Phase III Trial(2012)482 cited
- → A trial of gantenerumab or solanezumab in dominantly inherited Alzheimer’s disease(2021)354 cited
- → Two Phase 3 Trials of Gantenerumab in Early Alzheimer’s Disease(2023)248 cited
- → Gantenerumab reduces amyloid-β plaques in patients with prodromal to moderate Alzheimer’s disease: a PET substudy interim analysis(2019)209 cited
- → Functional validation of a genetic locus in the VEGFR-1 tyrosine kinase (TK) domain as a predictive marker for bevacizumab(2012)193 cited
- → VEGF pathway genetic variants as biomarkers of treatment outcome with bevacizumab: an analysis of data from the AViTA and AVOREN randomised trials(2012)186 cited
- → Biomarker results from the AVADO phase 3 trial of first-line bevacizumab plus docetaxel for HER2-negative metastatic breast cancer(2013)154 cited
- → Examining Treatment Outcomes with Erlotinib in Patients with Advanced Non–Small Cell Lung Cancer Whose Tumors Harbor Uncommon EGFR Mutations(2016)101 cited
- → The Transcriptional Coactivator Peroxisome Proliferator–Activated Receptor (PPAR)γ Coactivator-1α and the Nuclear Receptor PPARα Control the Expression of Glycerol Kinase and Metabolism Genes Independently of PPARγ Activation in Human White Adipocytes(2007)87 cited